The briefing
The phase 2 NRG-BR002 trial found that stereotactic body radiotherapy to oligometastatic sites did not extend progression-free survival compared with standard care in breast cancer. As a result, the planned phase 3 portion will not proceed.
Original headline
SBRT Ablation Fails to Extend PFS in Oligometastatic Breast Cancer